ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 860,95
1,54%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Soligenix Inc (SNGX)

  7. Soligenix Inc (SNGX) Actualités

SNGX Soligenix Inc

0,418
0,0135 (3,34%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Soligenix Inc SNGX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0135 3,34% 0,418 01:59:38
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,402 0,3958 0,4297 0,4045 0,4045
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202413:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
18/4/202414:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
15/4/202413:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
11/4/202413:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
03/4/202413:30PRNUSSoligenix Announces Agreement on the Design of a Second..
15/3/202412:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
08/2/202413:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
25/1/202413:30PRNUSSoligenix to Present at The Microcap Conference
08/1/202413:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
04/1/202413:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
02/1/202413:30PRNUSSoligenix Announces Publication Demonstrating Complete..
22/12/202322:05EDGAR2Form 8-K - Current report
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:03EDGAR2Form 8-K - Current report
08/12/202323:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202322:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/12/202313:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
30/11/202313:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
17/11/202322:05EDGAR2Form 8-K - Current report
17/11/202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
13/11/202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202313:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
20/10/202322:05EDGAR2Form 8-K - Current report
20/10/202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
17/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
17/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202322:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202313:30PRNUSSoligenix to Present at The ThinkEquity Conference
13/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/9/202313:30PRNUSSoligenix Announces Achievement of Two-Year Stability with..
22/9/202322:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/9/202322:05EDGAR2Form 8-K - Current report
22/9/202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
15/9/202322:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
15/9/202322:05EDGAR2Form 8-K - Current report
30/8/202322:05EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202323:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/8/202313:30PRNUSSoligenix Announces Recent Accomplishments And Second..
14/8/202322:09EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
10/8/202313:30PRNUSHyBryte™ Expanded Treatment Trial in Cutaneous T-Cell..
07/8/202322:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/8/202322:05EDGAR2Form DEF 14A - Other definitive proxy statements
11/7/202313:30PRNUSSoligenix Announces Expansion of SGX302 (Synthetic..

Dernières Valeurs Consultées

NASDAQ
SNGX
Soligenix
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés